<DOC>
	<DOCNO>NCT00352560</DOCNO>
	<brief_summary>The main purpose study compare mean AERP treatment group base hypothesis subject paroxysmal AF , Irbesartan prevent electrophysiological remodel result prolonged atrial effective refractory period relative ( AERP ) placebo .</brief_summary>
	<brief_title>Electrophysiological Effects Irbesartan Patients With Paroxysmal Atrial Fibrillation ( AF )</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Recurrent PAF indication catheter ablation Struct . Cardiopathy Mitral valve disease VEF &lt; 40 % Myocardiopathy LVH cardiac surgery AF reversible QT c &gt; 450 Recent MI/stroke , severe HTN Requirement ACEI/ARBs Coronary synd. , HTA , liver disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Patients Paroxysmal Atrial Fibrillation ( PAF )</keyword>
</DOC>